Overview

rs4244285 is a genetic variant on gene CYP2C19.

This variant is located on chromosome 10. The variations at position 94781859 are the genetic letters A/A, G/G, A/G

Since humans have each twice (one from each parent), these letter-variations occur on both chromosomes. People can have the same or different letters on both chromosomes. Every person's individual variation combination is referred to as genotype. For variant rs4244285 there are 3 currently known genotypes : A/A, G/G or A/G

Short Overview

Variant Location

rs4244285 is located on gene CYP2C19 in chromsome 10. Use the genome browser to explore the location of rs4244285 and its genetic neighbourhood.

Conditions & Traits

rs4244285 affects the following conditions and traits:

There are currently 0 conditions and 0 traits associated with rs4244285.

Pathogenicity

rs4244285 affects the following conditions:

There are currently 0 conditions associated with rs4244285.

Pharmacogenetics

rs4244285 affects the following drugs:

Genome Browser

This interactive browser visualizes what no human can see with the naked eye - our DNA. From a down to a specific position on a . The position you are looking at here is the exact location of variant rs on gene CYP2C19. Explore more variants and their effects on the body by browsing left and right along the DNA strand.

Loading Genome Browser...

Did you know genetic variants affect drugs?

Mutations are changes in genes and genetic variations are differences in the DNA among people. Variants are tiny changes in just one piece of the DNA while haplotypes are groups of these changes that usually come together.

Dr. Wallerstorfer Dr. Wallerstorfer

Conditions & Traits of rs4244285

Current research shows 0 conditions and 0 traits.

Conditions

0

Pharmacogenetics

The genetic variant rs4244285 impacts how certain medications work in the body. This difference may cause some of us to require different dosage amounts to achieve the desired effects, while others might experience more apparent side-effects. As a result, healthcare providers may need to adjust prescriptions for those individuals with rs4244285. Ultimately, understanding our genetic makeup helps improve the overall effectiveness and usability of medications. Tailoring treatments based on genetics ensures a safer, more personalized healthcare experience.

Genotype
Level of evidence
Impacts
Summary
AA

Breakdown

Drug Effect

Side Effects

Dosage

Individuals with the genotype A/A have decreased Drug Effect and increased Side Effects to CYCLOPHOSPHAMIDE.

more info

AG

Breakdown

Drug Effect

Side Effects

Dosage

Individuals with the genotype A/G have increased Drug Effect and increased Side Effects to CYCLOPHOSPHAMIDE.

more info

GG

Breakdown

Drug Effect

Side Effects

Dosage

Individuals with the genotype G/G have increased Drug Effect and increased Side Effects to CYCLOPHOSPHAMIDE.

more info

Legend:

Increased

Decreased

No known effect

Genotype
Level of evidence
Impacts
Summary
AA

Breakdown

Drug Effect

Side Effects

Dosage

Individuals with the genotype A/A have decreased Breakdown to ETRAVIRINE.

more info

AG

Breakdown

Drug Effect

Side Effects

Dosage

Individuals with the genotype A/G have decreased Breakdown to ETRAVIRINE.

more info

GG

Breakdown

Drug Effect

Side Effects

Dosage

Individuals with the genotype G/G have increased Breakdown to ETRAVIRINE.

more info

Legend:

Increased

Decreased

No known effect

Genotype
Level of evidence
Impacts
Summary
AA

Breakdown

Drug Effect

Side Effects

Dosage

Individuals with the genotype A/A have increased Side Effects to FLUOROURACIL.

more info

AG

Breakdown

Drug Effect

Side Effects

Dosage

Individuals with the genotype A/G have increased Side Effects to FLUOROURACIL.

more info

GG

Breakdown

Drug Effect

Side Effects

Dosage

No summary available.

more info

Legend:

Increased

Decreased

No known effect

Genotype
AA
Impacts

Breakdown

Drug Effect

Side Effects

Dosage

Summary

Individuals with the genotype A/A have decreased Drug Effect and increased Side Effects to CYCLOPHOSPHAMIDE.

Level of evidence

More info

Genotype
AG
Impacts

Breakdown

Drug Effect

Side Effects

Dosage

Summary

Individuals with the genotype A/G have increased Drug Effect and increased Side Effects to CYCLOPHOSPHAMIDE.

Level of evidence

More info

Genotype
GG
Impacts

Breakdown

Drug Effect

Side Effects

Dosage

Summary

Individuals with the genotype G/G have increased Drug Effect and increased Side Effects to CYCLOPHOSPHAMIDE.

Level of evidence

More info

Legend:

Increased

Decreased

No known effect

Genotype
AA
Impacts

Breakdown

Drug Effect

Side Effects

Dosage

Summary

Individuals with the genotype A/A have decreased Breakdown to ETRAVIRINE.

Level of evidence

More info

Genotype
AG
Impacts

Breakdown

Drug Effect

Side Effects

Dosage

Summary

Individuals with the genotype A/G have decreased Breakdown to ETRAVIRINE.

Level of evidence

More info

Genotype
GG
Impacts

Breakdown

Drug Effect

Side Effects

Dosage

Summary

Individuals with the genotype G/G have increased Breakdown to ETRAVIRINE.

Level of evidence

More info

Legend:

Increased

Decreased

No known effect

Genotype
AA
Impacts

Breakdown

Drug Effect

Side Effects

Dosage

Summary

Individuals with the genotype A/A have increased Side Effects to FLUOROURACIL.

Level of evidence

More info

Genotype
AG
Impacts

Breakdown

Drug Effect

Side Effects

Dosage

Summary

Individuals with the genotype A/G have increased Side Effects to FLUOROURACIL.

Level of evidence

More info

Genotype
GG
Impacts

Breakdown

Drug Effect

Side Effects

Dosage

Summary

No summary available.

Level of evidence

More info

Legend:

Increased

Decreased

No known effect

Drugs related to rs4244285

All drugs that are linked to rs4244285 are listed here.

Studies and Sources

All of the resources below examine variant rs4244285

Genetic polymorphisms of metabolic enzymes and the pharmacokinetics of indapamide in Taiwanese subjects. (10/22/14)

Teng-Hsu Wang, Cheng-Huei Hsiong, Hsin-Tien Ho, Tung-Yuan Shih, San-Jan Yen, Hui-Hung Wang, Jer-Yuarn Wu, Benjamin Pei-Chung Kuo, Yuan-Tsong Chen, Shung-Tai Ho, Oliver Yoa-Pu Hu

PubMed: 24357089
Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer. (10/13/17)

Sung-Hsin Kuo, Shi-Yi Yang, San-Lin You, Huang-Chun Lien, Ching-Hung Lin, Po-Han Lin, Chiun-Sheng Huang

PubMed: 28178648
DISCLAIMER: The materials present on Genopedia.com, such as text, images, graphics, among other items (“Content”), are shared purely for informational reasons. This content should not replace professional health advice, medical diagnoses, or treatment procedures. Whenever you have health concerns or questions, it’s always recommended to engage with your doctor or another appropriate healthcare provider. If you read something on the Genopedia.com site, do not neglect professional medical counsel or delay in obtaining it. In case you believe you’re dealing with a medical crisis, get in touch with your medical professional or call emergency without delay. Genopedia.com doesn’t advocate for any particular medical tests, healthcare providers, products, methods, beliefs, or other data that could be discussed on the site. Please also note that the content, originally written in English and in part created with the help of artificial intelligence, is provided without any warranty, and any reliance on information offered by Genopedia.com, its staff, contributors invited by Genopedia.com, or site users is entirely at your own risk.
Genopedia © 2026 all rights reserved